Core Viewpoint - The Trade Desk, Inc. is facing allegations of issuing materially false and misleading statements regarding its AI forecasting tool, Kokai, which has led to execution challenges and negatively impacted revenue growth [1][2]. Group 1: Allegations and Impact - The complaint alleges that during the class period from May 9, 2024, to February 12, 2025, The Trade Desk experienced significant execution challenges in rolling out its AI tool, Kokai, transitioning clients from the older platform, Solimar [1]. - These execution challenges delayed the Kokai rollout, which in turn negatively impacted the company's business operations and revenue growth [1]. - As a result of these issues, the positive statements made by the company regarding its business and prospects were deemed materially false and misleading [1]. Group 2: Shareholder Actions - Shareholders who purchased shares of TTD during the specified class period are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to partake in any recovery [1][2]. - The deadline for shareholders to register for the class action is April 21, 2025, and they will be enrolled in a portfolio monitoring software for status updates throughout the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who incurred losses from misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Crocs, Inc. regarding a class action lawsuit alleging misleading statements and failure to disclose critical information about the company's revenue growth and inventory management during a specified period [1][2]. Summary by Sections Allegations - The lawsuit claims that during the class period from November 3, 2022, to October 28, 2024, Crocs, Inc. made materially false and misleading statements regarding the sustainability of HEYDUDE's revenue growth, which was largely driven by stocking third-party wholesalers and retailers after its acquisition in February 2022 [1]. - It is alleged that as retail partners began to destock excess inventory, the demand for products decreased, negatively impacting Crocs' financial results [1]. - The representations made by the defendants about the company's business operations and prospects were claimed to be materially false and misleading, lacking a reasonable basis [1]. Next Steps for Shareholders - Shareholders who purchased shares of CROX during the specified timeframe are encouraged to register for the class action, with a deadline set for March 24, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring system to receive updates throughout the case lifecycle [2]. Firm's Commitment - The Gross Law Firm is recognized nationally for its commitment to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [2][3]. Group 1: Allegations - The lawsuit claims that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [2]. - It is alleged that the company added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2]. - The complaint states that the Phase Two Trials lacked adequate data, particularly concerning the patient population size and the male-to-female ratio, which could affect the predictability of the KOASTAL-1 study results [2]. Group 2: Class Action Details - The class period for the lawsuit commenced on or about September 15, 2023, and shareholders are encouraged to register by April 7, 2025, to participate [1][3]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ready Capital Corporation (NYSE: RC).Shareholders who purchased shares of RC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/ready-capital-corporation-loss-submission-form/?id=137093&from=4CLASS PERIOD: Novemb ...

NEW YORK, March 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=137092&fr ...

Group 1 - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about Gardasil's expected revenue [1] - The class period for the lawsuit is from February 3, 2022, to February 3, 2025, during which Merck projected $11 billion in sales from Gardasil by 2030 [1] - On February 4, 2025, Merck announced it would not achieve the projected sales due to ceasing shipments to China, leading to a stock price decline of over 9% in one day [1] Group 2 - Shareholders are encouraged to register for the class action by April 14, 2025, to potentially become lead plaintiffs and receive updates on the case [2] - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements that inflated Merck's stock price [3]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Integral Ad Science Holding Corp. regarding a class action lawsuit due to alleged misleading statements and competitive pricing pressures affecting the company's performance [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 2, 2023, to February 27, 2024 [2]. - The complaint claims that IAS faced increased competitive pricing pressures, leading to price cuts to address weakening demand and slowing revenue growth [2]. - It is alleged that IAS's pricing function was no longer favorable, impacting its ability to sustain pricing and drive price increases [2]. Group 2: Impact of Competition - Pricing has become a key differentiator for IAS in closing major renewals and new deals, indicating a shift in market dynamics [2]. - The risks associated with competition leading to increased pricing pressure have materialized, contradicting IAS's public statements [2]. Group 3: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 31, 2025, to participate in potential recovery [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [3]. Group 4: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [4].

Core Viewpoint - Newmont Corporation is facing a class action lawsuit due to disappointing financial results and operational challenges, leading to a significant drop in its stock price [1][2]. Group 1: Allegations and Financial Impact - The class period for the lawsuit is from February 22, 2024, to October 23, 2024 [1]. - On October 23, 2024, Newmont announced disappointing EBITDA for Q3 2024, along with decreased production and increased operating costs [1]. - The company revealed that mining operations at its two Tier 1 assets would experience lower production than previously guided, with expectations of higher costs [1]. - Following the announcement, Newmont's stock price fell from $57.74 per share to $49.25 per share, a decline of approximately 14.5% [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by April 1, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Walgreens Boots Alliance, Inc. regarding a class action lawsuit due to alleged misleading statements and regulatory violations during a specified class period [1]. Group 1: Class Action Details - The class period for the lawsuit is from April 2, 2020, to January 16, 2025 [3]. - Allegations include that Walgreens engaged in widespread violations of federal law related to prescription medication dispensation and reimbursement [3]. - The lawsuit claims that Walgreens' revenues from prescription medication sales were unsustainable due to unlawful conduct, leading to materially false and misleading public statements [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 31, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - Intellia Therapeutics is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, leading to a significant drop in stock price after the company announced a halt in research and workforce reduction [3][4]. Group 1: Company Overview - Intellia Therapeutics, Inc. (NASDAQ: NTLA) is involved in developing treatments for genetic diseases, with a focus on its NTLA-3001 program [3]. - The company had previously expressed confidence in its timeline for the NTLA-3001 study, expecting to dose the first patient in the second half of 2024 [3]. Group 2: Allegations and Developments - The lawsuit alleges that Intellia failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference in the scientific community, making NTLA-3001 an inefficient program [3]. - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27% in 2025, which led to a stock price drop from $12.02 on January 8, 2025, to $10.20 on January 10, 2025 [3][4]. Group 3: Class Action Details - Shareholders who purchased NTLA shares between July 30, 2024, and January 8, 2025, are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4].